Kallo Inc. Stock: price and management transactions · United States · SEC (Form 4)

About Kallo Inc.

Kallo Inc. (ticker: KALO) is a United States company whose publicly available profile points to OTC trading rather than an established NYSE or NASDAQ listing at this time. For investors in France, Belgium, and Switzerland, the first takeaway is that the equity story is unusual and the information set is limited. Public SEC and OTC documents indicate that Kallo is a Nevada corporation, and older disclosures describe a business focused on healthcare-related software and services, including software intended to collect, organize, and interpret medical information from multiple sources. Some legacy filings also referred to broader healthcare infrastructure ambitions, but those statements were followed by significant regulatory scrutiny. The SEC suspended trading in Kallo’s securities in 2021 due to concerns about the accuracy of public disclosures and later pursued revocation of the company’s registration under Section 12(j). Those historical events are central to any assessment of the name. ([sec.gov](https://www.sec.gov/file/order-107)) From an operating perspective, Kallo appears to have been positioned as a very small-cap, high-risk, speculative issuer rather than a scaled healthcare technology platform. The public record does not support the conclusion that Kallo has a broad commercial footprint, a mature recurring revenue base, or a market position comparable with larger US-listed peers on NYSE or NASDAQ. The company’s disclosed business model has centered on software and data-structured applications related to healthcare, but current filings and open sources do not provide enough evidence to confidently identify a large installed base, a dominant product category, or measurable market share. That lack of detail is itself an important risk signal for outside investors. ([otcmarkets.com](https://www.otcmarkets.com/financialReportViewer?id=131017&symbol=KALO)) The company’s geographic footprint has also appeared historically cross-border. In older OTC certification materials, Kallo’s officers and directors were listed in Canada, while the issuer itself was identified as a US entity. That suggests a transnational management footprint, although current public materials do not provide enough granularity to map today’s operational headquarters with high confidence. Because the company’s information flow is sparse and the regulatory history is material, investors should treat any apparent business description as provisional unless it is backed by recent SEC filings or audited reporting. ([otcmarkets.com](https://www.otcmarkets.com/financialReportViewer?id=131017&symbol=KALO)) Recent developments that are clearly material are mostly regulatory rather than commercial. The SEC’s 2021 trading suspension and the subsequent revocation proceedings remain the most important public milestones visible in the record reviewed. I did not find reliable, recent, company-specific operating news that would justify a more constructive growth narrative. As a result, Kallo should be viewed as a disclosure-sensitive, event-driven microcap situation, where the key analytical focus is not product momentum but regulatory status, reporting quality, and whether the company can demonstrate a credible operating business over time. ([sec.gov](https://www.sec.gov/file/order-107))